CHU Helora — Clinical Trial Site

115 Registered trials

57 Currently recruiting

Organisation

CHU Helora

Location

La Louviere, Belgium

Identifier

ORG-100042541

Address

Rue Samiette 1, 1400, Belgium

Departments

#1006: Onco-Hématologie
#40059: Rhumatologie
0506
056002-Hématologie
1605: Hematology
3703; Reumatology
6044: Rheumatology
7102 Rhumatologie
BE30005:Hematology/Hematologie
cardiologie
Cardiology
Clinical Research Unit
Department of Oncology
Department of Endocrinology
Department of Hematology
Department of Medical Oncology
Department of Oncology
Department of Oncology and Hematology
Endocrinologie – Diabetologie
Gastro-enterology
Gastro-oncology
Gastroenterology
Hematologie
Hematology
Hematology Department
Hôpital Ambroise Paré
Hopital de La Louviere - Site Jolimont, Oncologie
Internal Medicine
Medical Oncology
N/A
NA
Neurology
Oncolgy
Oncologie
Oncologie médicale
Oncologie-Hématologie
Oncology
Oncology and Hematology
Oncology and Hematology departments
Orthopedic surgery and traumatology
Otorhinolaryngology
Pneumology
Pulmonology
Radiotherapy
Rheumatology
SEREC - Service de Recherche Clinique
Service de Recherche Clinique (SeReC), Level 5A

Clinical trials at this site (115)

Search interface

A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21
A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended

2023-503576-25-00 Severe Hypertriglyceridemia 5 2023-09-22
ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended

2022-500536-11-01 Moderately to severely active ulcerative colitis 5 2023-06-08
First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended

2022-501183-17-00 Non-Small Cell Lung Cancer 7 2023-02-23
Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat… Ended

2024-514714-12-00 Metastatic Pancreatic Ductal Adenocarcinoma 10 2022-11-11
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S… Ended

2024-513559-34-00 Small Cell Lung Cancer (SCLC) 5 2022-07-19
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu… Ended

2023-507189-17-00 Muscle-Invasive Urothelial Carcinoma of the Bladder 4 2022-01-09
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Advanced solid tumors 9 2021-07-28
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor tolebrutinib (SAR442168) (PERSEUS) Ended

2024-514495-41-00 Primary Progressive Multiple Sclerosis 5 2020-11-04
Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended

2022-501972-25-00 Locally Advanced Cervical Cancer 5 2020-04-06
A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended

2023-506528-95-00 Psoriatic Arthritis 5 2019-11-21
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Primary myelofibrosis, post-polycythemia vera myelofibr 5 2019-08-05
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended

2023-503673-38-00 Adults at high risk of cardiovascular events without pr 5 2019-05-24
Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open-… Ended

2024-516783-29-00 Severe allergic and eosinophilic asthma 6 2018-04-16
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (… Ended

2024-516904-40-00 Previously Untreated Diffuse large B-cell lymphoma (DLB 5 2018-03-27
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 Newly Diagnosed RARA-positive Adult Patients with Highe 5
Phase II study evaluating peptide-based immunotherapies as monotherapy for 3 weeks prior to standard treatment for head and neck cancer. Ended

2024-513447-82-00 squamous cell carcinoma of the head and neck 4
A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nons… Ended

2024-515393-27-00 Nonsquamous non-small cell lung cancer 4